Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03112681 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis
A Phase 2 study of Primary Biliary Cirrhosis, sponsored by Zydus Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 9
- Study locations
NCT03112681 is a Phase 2 study of Primary Biliary Cirrhosis that has completed, run by Zydus Therapeutics. The registered enrollment target is 37 participants, below the 1,437-participant average among 7 other Primary Biliary Cirrhosis trials with a reported enrollment target (97% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT03112681, a Phase 2 study of Primary Biliary Cirrhosis, has completed, sponsored by Zydus Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 9
- Study locations
Study Summary
prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability and efficacy of saroglitazar magnesium 2 mg, 4 mg in Patients with Primary Biliary Cholangitis (PBC). A total 36 subjects will be enrolled in a ratio of 1:1:1 to receive either saroglitazar magnesium 2 mg or saroglitazar magnesium 4 mg or placebo.
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG Saroglitazar magnesium 2 mg
- DRUG Saroglitazar magnesium 4 mg
Study Locations (9)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- Einstein Medical Center Philadelphia - Philadelphia
California
- California Liver Research Institute - Pasadena
Florida
- Schiff Center for Liver Diseases/University of Miami - Miami
Georgia
- Gastrointestional Specialists of Georgia - Marietta
Indiana
- Indiana University School of Medicine - Indianapolis
New Jersey
- Rutgers NJ Medical School - Newark
North Carolina
- Carolinas Healthcare System - Charlotte
Ohio
- Consultants for Clinical Research - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2017-08-18 |
| Est. Completion | 2020-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03112681
The ClinicalTrials.gov registry entry for NCT03112681 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,437-participant average among 7 other Primary Biliary Cirrhosis trials with a reported enrollment target (97% lower). The listed sponsor is Zydus Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Biliary Cirrhosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo Oral Tablet is the first listed.
NCT03112681 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Pennsylvania, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03112681 about?
NCT03112681 is a clinical study titled "Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis". prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability and efficacy of saroglitazar magnesium 2 mg, 4 mg in Patients with Primary Biliary Cholangitis (PBC). A total 36 subjects will be enrolled in a ratio of 1:1:1 to receive either saroglitazar ...
What is the current status of trial NCT03112681?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2017-08-18. Estimated completion is 2020-08-07.
What conditions does trial NCT03112681 study?
This clinical trial studies the following conditions: Primary Biliary Cirrhosis.
What interventions are being tested in trial NCT03112681?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Saroglitazar magnesium 2 mg (DRUG), Saroglitazar magnesium 4 mg (DRUG).
Who is sponsoring clinical trial NCT03112681?
This trial is sponsored by Zydus Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03112681 being conducted?
This trial has 9 study locations across California, Florida, Georgia, Indiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Biliary Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
COMPLETED · Phase 2
-
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
COMPLETED · Phase 2
-
Use of Fenofibrate for Primary Biliary Cirrhosis
COMPLETED · Phase 2
-
Biobank for Cholestatic Liver Diseases.
RECRUITING
-
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
ACTIVE NOT RECRUITING · Phase 3
-
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.